University of Pittsburgh (USA) employees reported first successful trial of a promising coronavirus vaccine SARS-CoV-2, which caused the COVID-19 pandemic. Rodent tests showed that the drug being developed forces the body produce antibodies necessary to neutralize the pathogen. ABOUT testing a potential coronavirus vaccine writes TASS.
“We already have experience developing vaccines against viruses like this types are, in particular, SARS-CoV and MERS-CoV. These pathogens taught us to create immunity against coronaviruses – especially for this the spike protein that is present on the surface of the membrane is important the virus. We knew which way to look to create the vaccine. from a new pathogen, “said Andrea Gambotto, Representative of the Department of Surgery, University of Pittsburgh.
The drug in question was called PittCoVacc. is he based on a proven methodology for creating vaccines – that is, uses parts of viral proteins to form immunity. The vaccinations common in the world from flu.
Testing PittCoVacc in laboratory mice showed that the level of antibodies to the virus rises within two weeks after the introduction of the vaccine. It is not yet known how the vaccine will affect the body of mice in the long run – this requires longer and more extensive testing. But the job of creating SARS-CoV-2 vaccines, as you can see, are maintained in the right direction.